自体卵巢癌细胞毒T淋巴细胞(OCTL)(北京纬晓生物技术)(Autologousovarian Cancer Cells To Cytotoxic T Lymphocytes(OCTL)(Beijing Weixiao Biological Technology Development))

概要

基本信息

药物类型

T细胞疗法

别名

6B11抗独特型微抗体负载DC和细胞因子诱导的自体卵巢癌杀伤细胞、OCTL

+ [1]

靶点-

作用机制

免疫调节剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

北京大学人民医院北京纬晓生物试剂技术有限公司

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)临床1期

特殊审评-

登录后查看时间轴

关联

3

项与自体卵巢癌细胞毒T淋巴细胞(OCTL)(北京纬晓生物技术) 相关的临床试验

CTR20190733 / Recruiting临床1期

6B11抗独特型微抗体负载树突状细胞和细胞因子诱导的自体卵巢癌杀伤细胞注射液（6B11-OCIK注射液）治疗耐药复发型卵巢癌的I期临床研究

主要目的：评价6B11-OCIK注射液与化疗联合治疗耐药复发型卵巢癌（包括上皮卵巢癌，原发性腹膜癌或输卵管癌）受试者的安全性和耐受性，确定6B11-OCIK注射液治疗最大耐受剂量（MTD）和/或后续推荐剂量（RD）。次要目的：初步评价6B11-OCIK注射液输注人体后对受试者免疫系统的影响；初步评价6B11-OCIK注射液与化疗联合治疗耐药复发型卵巢癌（包括上皮卵巢癌，原发性腹膜癌或输卵管癌）受试者的疗效；初步研究基线时肿瘤组织中OC166-9抗原表达情况与疗效之间的相关性。探索性目的：初步研究6B11-OCIK注射液输注人体后对受试者以下指标的影响，中性粒细胞/淋巴细胞比值（NLR）、淋巴细胞/单核细胞（LMR）、血小板/淋巴细胞（PLR）。

开始日期2022-01-19

申办/合作机构

北京纬晓生物试剂技术有限公司

[+1]

NCT03542669 / Unknown status临床1期IIT

A Phase I Study of Autologous Killer Cell Injection Induced by Dendritic Dells Loaded With 6B11 Anti-idiotype Minibody (6b11 - OCIK Injection) Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer

This is an open, single-arm, phase I clinical trial to evaluate safety and efficacy and of 6b11-OCIK injection in the treatment of recurrent drug-resistant ovarian cancer

开始日期2018-08-03

申办/合作机构

北京大学人民医院

[+1]

CTR20171659 / Suspended临床1期

6B11-OCIK注射液治疗耐药复发型上皮性卵巢癌I期临床研究

主要目的：确定 6B11-OCIK 注射液治疗耐药复发型上皮性卵巢癌受试者的最大耐受剂量（MTD）；次要目的：评价自体 6B11-OCIK 注射液治疗耐药复发型上皮性卵巢癌受试者的安全性和耐受性；探索性目的： 1.初步了解自体 6B11-OCIK 注射液对耐药复发型上皮性卵巢癌受试者的疗效。 2.评价自体 6B11-OCIK 注射液对耐药复发型上皮性卵巢癌受试者免疫系统的影响。

开始日期2018-07-25

申办/合作机构

北京大学人民医院

[+1]

100 项与自体卵巢癌细胞毒T淋巴细胞(OCTL)(北京纬晓生物技术) 相关的临床结果

登录后查看更多信息

100 项与自体卵巢癌细胞毒T淋巴细胞(OCTL)(北京纬晓生物技术) 相关的转化医学

登录后查看更多信息

100 项与自体卵巢癌细胞毒T淋巴细胞(OCTL)(北京纬晓生物技术) 相关的专利（医药）

登录后查看更多信息

4

项与自体卵巢癌细胞毒T淋巴细胞(OCTL)(北京纬晓生物技术) 相关的文献（医药）

2016-11-21·Drug Delivery2区 · 医学

Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo

2区 · 医学

ArticleOA

作者: Li, Huipeng ; Ping, Qineng ; Yuan, Dongfen ; Sun, Minjie

Octreotide had been exploited as a targeting ligand for nanoparticle tumor localization overexpressing somatostatin receptor. In addition to particle size and other physiochemical properties, ligand density had great influence on the delivery of active targeted nanoparticles. Herein, octreotide-targeted liposomal doxorubicin was constructed with different ligand density by post-inserting HSPE-PEG₄₀₀₀-Octreotide into pre-formed liposome. The octreotide ligand insertion was confirmed by activity detection of octreotide in HSPE-PEG₄₀₀₀-Octreotide with synchronous fluorescence. 1% octreotide density could achieve the best uptake efficiency on NCI-H-446 and SMMC-7721 cell lines among all liposomes. Octreotide-grafted long-circulating liposome (Oct-SSL) was prepared based on 1% octreotide density. The results showed that the insertion of PEG reduced cellular uptake and cytotoxicity. However, Oct-SSL showed a higher MRT compared with Oct-L showing the relative higher long circulating effect in pharmacokinetic study. Oct-SSL also showed tumor growth inhibition of twofold compared with other groups in Heps xenograft model mice. Oct-SSL with suitable ligand density and PEG modification exhibited significant effective tumor targeting for antitumor drug delivery.

2012-09-01·Brain Research4区 · 医学

The protection by Octreotide against experimental ischemic stroke: Up-regulated transcription factor Nrf2, HO-1 and down-regulated NF-κB expression

4区 · 医学

Article

作者: Xiaolin Zhang ; Lan Zhang ; Xiangjian Zhang ; Jian Zhang ; Xumeng Zhao ; Zongjie Liu ; Lipeng Dong ; Lili Cui ; Chaohui Wang ; Linyu Chen ; Lina Wang ; Yanhua Li ; Yinxue Xing ; Xue Bai

BACKGROUNDInflammatory and oxidative damage play a pivotal role in cerebral ischemic pathogenesis and may represent a therapeutic target. Octreotide (OCT) has been proved to elicit a variety of biological effects through its anti-inflammatory and anti-oxidant properties in the treatment of severe acute pancreatitis and ischemia-reperfusion injury in retina and intestine. However little is known regarding the effect of OCT in ischemic stroke. Here, we designed this study to investigate the protective effect of OCT in ischemic stroke and explore the potential underlying mechanisms.METHODSMale Sprague-Dawley rats were subjected to permanent middle cerebral artery occlusion (pMCAO) and randomly divided into four groups: Sham (sham-operated), MCAO (pMCAO+0.9% saline), OCT-L (pMCAO+OCT 50μg/kg) and OCT-H (pMCAO+OCT 100μg/kg) groups. OCT was administered intraperitoneally immediately after stroke. Neurological deficit scores, infarct volume and brain water content were measured at 24h after stroke. Immunohistochemical staining and western blot were used to analyze the expressions of Nrf2, HO-1 and NF-κB. SOD and MDA were measured by spectrophotometer.RESULTSCompared with MCAO group, OCT significantly alleviated neurological deficit, lessened infarct volume and brain edema (P<0.05), upregulated the expression of Nrf2, HO-1 and SOD (P<0.05), and decreased the expression of NF-κB and MDA (P<0.05).CONCLUSIONSOCT protected the brain against cerebral ischemic damage; this effect may be through upregulation of transcription factor Nrf2, HO-1 and downregulation of NF-κB expression.

2008-12-01·Ai zheng = Aizheng = Chinese journal of cancer

[Specific immune cell therapy against ovarian cancer in vivo and in vitro].

Article

作者: Fu, Tian-Yun ; Cheng, Hong-Yan ; Cheng, Ye-Xia ; Zhang, Guo ; Ye, Xue ; Cui, Heng ; Chang, Xiao-Hong ; Zhang, Li ; Guo, Hui-Fang

BACKGROUND & OBJECTIVE6B11minibody (6B11mini), an anti-idiotypic vaccine against human ovarian cancer, has been proven to induce specific humoral and cellular immunity against ovarian cancer in vivo and in vitro. This study was to investigate the safety and efficacy of using 6B11mini as an antigen to treat ovarian cancer.METHODSAfter being loaded with purified 6B11mini, dendritic cells (DCs) were co-cultured with peripheral blood mononucleocytes (PBMNC) and stimulated by various cytokines, including CD3 monoclonal antibody,interleukin-2, interferon-gamma, to obtain 6B11mini-ovarian-cytokine-induced-killer cells (6B11-O-CIK). Tumor-forming ability was determined using soft agar colony-forming assay in vitro and nude mice xenografts in vivo. The acute toxicity of 6B11-OCIK at different doses was observed in BALB/c mice. Cytotoxicity of 6B11-OCIK to different target cells was detected using 51Cr release test in vitro. The ovarian tumor model was established using severe combined immune deficiency (SCID) mice transplanted with human ovarian cancer cell line SKOV3. The tumor growth was detected after injection of 6B11-OCIK into SCID mice. Injection of CIK, PBMNC and physiological saline were used as controls.RESULTSAfter a cultural period of 14 days in soft agar, SKOV3 cell clones were well formed with a ratio of 50%; while 6B11-OCIK, CIK and PBMNC did not form any clones. All nude mice injected with human cervical carcinoma cell line HeLa (positive control) grew tumors after 14 days, and mice injected with 6B11-OCIK, CIK, PBMNC and normal human fetal lung fibroblast WI-38 cells did not form tumors after 13 weeks. BALB/c mice did not show any abnormal response half an hour after the administration of 6B11-OCIK cells at different doses. Mice were sacrificed 13 days after treatments, but no distinct abnormality of the main organs were found. 6B11-OCIK exerted specific cytotoxicity against tumor cells with positive OC166-9, which was related to the limitation of MHC. The tumor weights of SCID mice transplanted with SKOV3 cells were significantly lighter in 6B11-OCIK treatment group than in the saline group(P=0.023); while the tumor weights were not significantly different between the 6B11-OCIK group with CIK and the PBMNC group(P=0.540; P=0.285).CONCLUSIONSThe application of 6B11-OCIK in vivo has reached the safety standard. 6B11-OCIK has the inhibitory effect on the growth of ovarian cancer cells.

100 项与自体卵巢癌细胞毒T淋巴细胞(OCTL)(北京纬晓生物技术) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
铂耐药性卵巢癌	临床1期	中国	北京纬晓生物试剂技术有限公司	2018-08-03
铂耐药性卵巢癌	临床1期	中国	北京大学人民医院	2018-08-03
复发性卵巢癌	临床1期	中国	北京大学人民医院	2018-08-03
复发性卵巢癌	临床1期	中国	北京纬晓生物试剂技术有限公司	2018-08-03
卵巢上皮癌	临床1期	中国	北京大学人民医院	2018-07-25
卵巢上皮癌	临床1期	中国	北京纬晓生物试剂技术有限公司	2018-07-25